Evidence map›Paper›PMID 38231313›Full record

Trial reportBreast cancer research and treatment2024

Identification of patient subgroups who benefit from a behavioral intervention to improve adjuvant endocrine therapy adherence: a randomized-controlled trial.

Emily A Walsh, Kathryn Post, Katina Massad, Nora Horick, Michael H Antoni, Frank J Penedo, Steven A Safren, Ann H Partridge, Jeffrey Peppercorn, Elyse R Park and 3 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Breast cancer research and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03837496 (Symptom-Targeted Randomized Intervention for Distress and Adherence to Adjuvant Endocrine Therapy), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03837496 nacompletednot on this map

Symptom-Targeted Randomized Intervention for Distress and Adherence to Adjuvant Endocrine Therapy (STRIDE) Among Breast Cancer Survivors: A Pilot Feasibility Trial

TypeinterventionalSponsorMassachusetts General HospitalRan2019 to 2021Enrolled100ConditionsBreast Cancer, Adherence, MedicationArmsSTRIDE, Medication Monitoring Control
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Emily A WalshDepartment of Psychology, University of Miami, 5665 Ponce de Leon Blvd, Fifth Floor, Coral Gables, FL, 33146, USA. Eaw99@miami.edu.ORCID http://orcid.org/0000-0002-0874-2645
Kathryn PostMassachusetts General Hospital, Boston, MA, USA.
Katina MassadUniversity of Missouri School of Medicine, Columbia, MO, USA.
Nora HorickMassachusetts General Hospital, Boston, MA, USA.
Michael H AntoniDepartment of Psychology, University of Miami, 5665 Ponce de Leon Blvd, Fifth Floor, Coral Gables, FL, 33146, USA.
Frank J PenedoDepartment of Psychology, University of Miami, 5665 Ponce de Leon Blvd, Fifth Floor, Coral Gables, FL, 33146, USA.
Steven A SafrenDepartment of Psychology, University of Miami, 5665 Ponce de Leon Blvd, Fifth Floor, Coral Gables, FL, 33146, USA.
Ann H PartridgeHarvard Medical School, Boston, MA, USA.
Jeffrey PeppercornMassachusetts General Hospital, Boston, MA, USA.
Elyse R ParkMassachusetts General Hospital, Boston, MA, USA.
Jennifer S TemelMassachusetts General Hospital, Boston, MA, USA.
Joseph A GreerMassachusetts General Hospital, Boston, MA, USA.
Jamie M JacobsMassachusetts General Hospital, Boston, MA, USA.

Funding

Improving Adherence to Endocrine Therapy in Breast Cancer SurvivorsK07CA211107 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI JACOBS, JAMIE MICHELE · 2017 to 2021
$875k
Division of Cancer Prevention, National Cancer Institute K07CA211107NCI NIH HHS K07 CA211107
6 · The paper itself

Abstract

purposeAdjuvant endocrine therapy (AET) reduces breast cancer morbidity and mortality; however, adherence is suboptimal. Interventions exist, yet few have improved adherence. Patient characteristics may alter uptake of an intervention to boost adherence. We examined moderators of the effect of a virtual intervention (STRIDE; #NCT03837496) on AET adherence after breast cancer.

methodsAt a large academic medical center, patients taking AET (N = 100; M

resultsAge (B = 0.05, SE = 0.02, p = 0.003) and AET-related symptom distress (B = -0.04, SE = 0.02, p = 0.02) moderated condition effect on self-reported adherence while anxiety (B = -1.20, SE = 0.53, p = 0.03) and depressive symptoms (B = -1.65, SE = 0.65, p = 0.01) moderated objective adherence effects. AET-specific concerns approached significance (B = 0.91, SE = 0.57, p = 0.12). Participants who received STRIDE and were older or presented with lower anxiety and depressive symptoms or AET-related symptom distress exhibited improved adherence. Post hoc analyses revealed high correlations among most moderators.

conclusionsA subgroup of patients who received STRIDE exhibited improvements in AET adherence. The interrelatedness of moderators suggests an underlying profile of patients with lower symptom burden who benefitted most from the intervention. STUDY REGISTRATION: NCT03837496.

Indexed as

Breast NeoplasmsAntineoplastic Agents, HormonalChemotherapy, AdjuvantFemaleHumansMedication AdherenceMiddle AgedSurveys and QuestionnairesAntineoplastic Agents, HormonalAdherenceAdjuvant endocrine therapyBreast cancerPsychosocial interventionSymptom burdenSymptom profile

Identifiers

PMID38231313
PMCPMC11937626

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.